More than $40 trillion. That’s with a T. 

Those were the estimated claims facing OxyContin maker Purdue Pharma and its founders, the Sackler family, when a bankruptcy court enjoined all litigation against them in 2019. In exchange for getting the Sacklers—who did not enter bankruptcy and who had all left the board of the company by that time—to chip in billions to fund a bankruptcy settlement, the company’s reorganization plan contained several nonconsensual releases that, in effect, permanently barred certain third-party claims against the Sacklers

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]